ArticleHuman vaccines & immunotherapeutics2023
Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study.
Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis.Vaccines · 2024Article
- Article
- Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.Vaccines · 2023Article
- Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The durability of antibody responses induced by the three-dose of CoronaVac vaccination, especially against SARS-CoV-2 Omicron subvariants, remains unclear. Here in our study, 160 plasma samples from 32 healthy individuals who received three doses of CoronaVac were longitudinally tracked for a period of 20 months. The results showed that a third homologous dose of CoronaVac efficiently increased the SARS-CoV-2 IgG and neutralizing antibody titers and enhanced neutralization activity against Omicron subvariants. The levels of IgG and neutralizing antibody declined from peak levels but remained detectable in most subjects over the course of the next 10-12 months. However, most of the individuals kept neutralizing titers against ancestral Wuhan-Hu-1, while they lost their neutralizing activities against Omicron B.1.1.529, BA.2, BA.4/BA.5, and BA.2.75.2 subvariants at 10-12 months post the third vaccination. Our results suggest that a fourth dose of vaccine may be necessary for uninfected individuals to confer higher neutralization against emerging Omicron subvariants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.